Contemporary Issues in Lung CancerJones & Bartlett Publishers, 2009 M02 12 - 364 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective Second Edition is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. |
From inside the book
Results 1-5 of 81
Page 3
... increased the funding to $242.9 million for the fiscal year 2006 (NCI, 2008a). In comparison, NCI OSPA spent a larger sum of $522.6 million for breast cancer research in 2002 and $584.7 million in 2006 (NCI, 2008b). Also, NCI offers ...
... increased the funding to $242.9 million for the fiscal year 2006 (NCI, 2008a). In comparison, NCI OSPA spent a larger sum of $522.6 million for breast cancer research in 2002 and $584.7 million in 2006 (NCI, 2008b). Also, NCI offers ...
Page 7
... increased survival in early stage disease, whereas squamoid tumors are associated with increased sur- vival in advanced disease. SCLC is in a separate category because of its rapid proliferation, high growth fraction, and the early ...
... increased survival in early stage disease, whereas squamoid tumors are associated with increased sur- vival in advanced disease. SCLC is in a separate category because of its rapid proliferation, high growth fraction, and the early ...
Page 10
... increased by radon gas, discussed more in depth in Chapter 11, Environmental Risk: Indoor Radon Exposure. Radon gas is the second leading cause of lung cancer (Ettinger, et al., 2008). It is especially risky for underground miners ...
... increased by radon gas, discussed more in depth in Chapter 11, Environmental Risk: Indoor Radon Exposure. Radon gas is the second leading cause of lung cancer (Ettinger, et al., 2008). It is especially risky for underground miners ...
Page 11
... increases the risk of developing lung cancer (Ettinger, et al., 2008). It is es- timated that 3-4% of lung cancer is related to as- bestos exposure (Omenn et al., 1986). These substances, though, account for afar lower num- ber of lung ...
... increases the risk of developing lung cancer (Ettinger, et al., 2008). It is es- timated that 3-4% of lung cancer is related to as- bestos exposure (Omenn et al., 1986). These substances, though, account for afar lower num- ber of lung ...
Page 17
... also emerging distinction at the cellular level between types of cancer in regards to the clinical outcomes. Recent molecular developments are leading to increasing knowledge about the 17. Chapter. 2. Chapter 2 Biology of Lung Cancer.
... also emerging distinction at the cellular level between types of cancer in regards to the clinical outcomes. Recent molecular developments are leading to increasing knowledge about the 17. Chapter. 2. Chapter 2 Biology of Lung Cancer.
Contents
Oncology Treatment Modalities | 45 |
Special Issues Facing Individuals with Lung Cancer | 117 |
Psychosocial Issues of Individuals with Lung Cancer | 231 |
Assistance and Resources for Individuals Facing Lung Cancer | 255 |
Media and Future Research Directions | 301 |
Index | 353 |
Other editions - View all
Common terms and phrases
adjuvant agents aprepitant associated bevacizumab breathing breathlessness Bruera carboplatin carcinoma cell lung cancer chemotherapy chronic cisplatin Clinical Oncology clinical trials combination diagnosis disease docetaxel dose drug dyspnea EGFR erlotinib etoposide evaluation evidence-based factors fatigue gefitinib gemcitabine gene improve increased individuals indoor radon Internet intervention irinotecan Journal of Clinical lung cancer patients Medicine ment metastatic months NCCN nicotine non-small cell lung NSCLC Nursing Forum Oncology Nursing Oncology Nursing Forum paclitaxel palliative palliative care patient navigation patients and families patients with lung pemetrexed phase potential pulmonary quit smoking radiation therapy radiotherapy radon randomized receptors regimen reported resection respiratory response rate risk role SCLC score screening Sekido side effects small cell lung smoking cessation stage strategies support group surgical survival rate Symptom Management Table tients tion tobacco topotecan toxicity treat treatment tumor versus vinorelbine weight loss